Title : Phase I study of tivantinib in Japanese patients with advanced hepatocellular carcinoma: Distinctive pharmacokinetic profiles from other solid tumors.

Pub. Date : 2015 May

PMID : 25711511






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 A c-Met inhibitor tivantinib is a candidate anticancer agent for patients with hepatocellular carcinoma (HCC), and CYP2C19 is the key metabolic enzyme for tivantinib. ARQ 197 cytochrome P450 family 2 subfamily C member 19 Homo sapiens